CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. by Krummel, MF & Allison, JP
UCSF
UC San Francisco Previously Published Works
Title
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Permalink
https://escholarship.org/uc/item/9vc4811r
Journal
The Journal of experimental medicine, 182(2)
ISSN
0022-1007
Authors
Krummel, MF
Allison, JP
Publication Date
1995-08-01
DOI
10.1084/jem.182.2.459
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CD28 and CTLA-4 Have Opposing Effects 
on the Response of T ceils to Stimulation 
By Matthew F. Krummel and James p. Allison 
From the Department ofMolecular and Cell Biology and Cancer Research Laboratory, 
University of California, Berkeley, California 94720 
Summary 
The importance ofthe B7/CD28/CTLA-4 molecules has been established in studies of antigen- 
presenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28. 
CTLA-4, a T cell surface glycoprotein that is related to CD28, can also interact with B7-1 and 
B7-2. However, less is known about the function of CTLA-4, which is expressed athighest 
levels after activation. We have generated anantibody to CTLA-4 to investigate he consequences 
of engagement of this molecule in a carefully defined system using highly purified T cells. We 
show here that the presence of low levels of B7-2 on freshly explanted T cells can partially inhibit 
T cell proliferation, and this inhibition is mediated by interactions with CTLA-4. Cross-linking 
of CTLA-4 together with the TCK and CD28 strongly inhibits proliferation and IL-2 secretion 
by T cells, Finally, results how that CD28 and CTLA-4 deliver opposing signals that appear 
to be integrated by the T cell in determining the response to activation. These data strongly 
suggest that the outcome of T cell antigen receptor stimulation isregulated by CD28 costimulatory 
signals, as well as inhibitory signals derived from CTLA-4. 
R~ cent work has demonstrated that CD28, a protein ex- pressed on resting and activated cells, is the major 
costimulatory molecule for proliferation ofT cells (1-3). CD28 
engagement via antibodies augments he proliferation of T 
cells in response to immobilized anti-TCR antibodies (4). 
Additionally, antibody engagement can supply costimulation 
to T cells encountering APCs deficient in costimulation (4, 
5) and prevents he resultant anergic state that otherwise occurs 
in long-term clones (4). Finally, Fab fragments ofanti-CD28 
can fully block proliferation by costimulation competent 
APCs (4). 
Several lines of evidence indicate that B7-1 (CD80) and 
B7-2 (CD86) (6) are the major costimulatory ligands on the 
APC. First, a chimeric fusion protein of CD28 binds B7-1 
and B7-2 (7, 8). Second, anti-B7 antibodies block T cell acti- 
vation by a variety of APCs (9, 10). Finally, induction of 
expression fB7-1 or B7-2 by transfection with cDNAs confers 
costimulatory activity on cells that do not otherwise provide 
costimulation (11-14). Interestingly, APCs and especially den- 
dritic cells, which are thought o be involved in the early 
phases of T cells activation, express moderate l vels of func- 
tional B7-2 without activation (6, 15). These levels increase 
nearly 100-fold with overnight activation, enhancing their 
APC function. 
B7-1 and B7-2 also bind CTLA-4, a close relative of CD28. 
Chimeric fusion proteins consisting of the ectodomain of 
CTLA-4 bind B7-1 and B7-2 (8, 16-18) and can block T 
cell activation by costimulation competent accessory cells (10, 
12). Notably, studies with soluble fusion protein indicate that 
CTLA-4 binds both B7 family members with an affinity "~20- 
fold higher than that of CD28. This higher affinity probably 
accounts for the ability of the CTLA-4 Ig fusion protein to 
block costimulation i vitro (10, 12) and to suppress graft 
rejection and antibody production in vivo (19, 20). 
While the ability of CTLA-4 fusion proteins to bind CD28 
ligands and block T cell activation is clear, the function of 
the native molecule has been obscure. Originally identified 
as cDNA cloned from a subtracted CTL clone library (21), 
CTLA-4 is homologous toCD28, especially in the extracel- 
lular domain, and both contain aconserved sequence motif, 
MYPPY, thought to be involved in B7 binding (22). Recent 
work has shown that CTLA-4 mRNA is expressed within 
a few hours of activation (23). Studies with mAbs to both 
human and mouse CTLA-4 demonstrated surface xpression 
within 48 h of activation. However, functional studies have 
led to different conclusions about its role in activation. Linsley 
et al. in a study of human T cells found that anti-CTLA-4 
antibodies enhanced proliferation of T cells activated with 
anti-CD3 and anti-CD28, suggesting that the function of 
CTLA-4 was to augment or sustain costimulation (24, 25). 
Walunas et al. found that both intact and monovalent frag- 
ments of antibodies to mouse CTLA-4 enhanced T cell re- 
sponses in allogeneic MLR, but that intact antibody inhibited 
proliferation under conditions where Fc receptor cross-linking 
was provided (26). These results uggest that CTLA-4 might 
play a role in negative regulation of T cell activation. 
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We describe here an analysis of CD28 and CTLA-4 sig- 
naling on highly purified T cells, noting the presence of B7 
on the T cells themselves. The results indicate that the two 
molecules have opposing effects on lymphokine production 
and proliferation, and that the outcome of T cell activation 
is determined by integration of signals transduced by these 
two molecules. 
Materials and Methods 
Immunization and Hybn'doma Production. 6-wk-old golden Syrian 
hamsters received five footpad injections of 50 #1 (packed volume) 
heat-killed Staphylococcus A bacteria coated with •100 #g CTLA- 
4Ig (27) and suspended in 0.2 ml PBS. 3 d after the final injection, 
draining lymph nodes were removed, and lymphocytes were iso- 
lated and fused with the P3X3.Ag8.653 myeloma line using a stan- 
dard polyethylene glycol fusion technique (28). Hybridoma super- 
natants were tested for reactivity to CTLA-4 Ig and for a lack of 
reactivity to CD4 Ig by ELISA (29). Hybridomas from positive 
wells were repetitively cloned by limiting dilution in the presence 
of irradiated mouse thymocyte f eder layers. Antibody 9H10 was 
specific for CTLA-4 by three criteria: (a) Reactivity against CTLA-4 
Ig but not CD4 lg; (b) the ability to block CTLA-4 Ig binding 
to B7 transfectants; (c)the ability to stain activated T ceils but not 
freshly isolated T cells; and (d) the ability to stain a CTLA-4 trans- 
fectant but not control transfectants. 
Antibodies. Antibodies used include anti-CD3 clone 50(02 (30), 
anti-CD28 clone 37.51 (31), anti-B7-1 clone 1610A (9), anti-B7-2 
(17), anti-Vqr3 clone 536 (32), anti-class II MHC clone 28-16-8s 
(33), and anti-IA a/b clone BP107 (34). Conjugates of these anti- 
bodies were prepared in our laboratory. PE, biotin, and FITC con- 
jugates of anti-CD4 and anti-CD8 were purchased from CALTAG 
Laboratories (South San Francisco, CA) and PharMingen (San 
Diego, CA). 
T Cell Activation Cultures. Spleens from 4-6-wk-old BALB/c 
mice were harvested and minced, and suspensions were treated with 
Geys RBC lysis solution (35). Cells were cultured in RPMI con- 
taining 10% FCS and soluble anti-CD3 antibody at 10 #g/ml. 
Flow Cytometry. 2 x 10 s cells were suspended in 10 #1 ice-cold 
PBS/1% calf serum/0.05% sodium azide. Antibodies were added 
for 30 min followed by two 4-ml washes in PBS/calf serumAo- 
dium azide. Data were acquired on a FACScan | (Becton Dickinson 
and Co. (Mountain View, CA) and the LYSIS II program was used 
to electronically gate on relevant populations. 
Proliferation Assays. LN cells were isolated from 6-8-wk-old 
BALB/c mice (Charles River Laboratories, Wilmington, MA). Iso- 
lated lymphocytes were obtained by mincing and filtration through 
nylon sieves. Cells were then treated with anti-class II antibodies 
28.16.8s and BP107 and a mixture of rabbit and guinea pig com- 
plement (Accurate Chemical and Scientific Corp., Westbury, NY). 
Viable cells were isolated over lympholyte 1.119 (Sigma Chemical 
Co., St. Louis, MO) and residual Ig-positive cells were removed 
by repetitive panning on rabbit anti-mouse IgG coated tissue cul- 
ture plates. Typical preparations analyzed by FACS | were typically 
found to be 99% Thyl.2 + with <0.5% B220-positive cells. 
Round-bottomed 96-well plates were used for all assays. Where 
indicated, wells were coated with anti-CD3 at 0.1/xg/ml in 50-t~l 
vol for 2 h at 37~ then washed extensively and blocked for 30 
rain at 37~ with complete RPMI 1640. T cells were added at 
l0 s per weli in 200/zi complete ILPMI 1640. For soluble assays, 
anti-CD28 was added at a 1:1,000 dilution of ascites, anti-CTLA-4 
was added at 10 #g/ml, and B7 antibodies were added at 2.5 #g/ml 
and 10/zg/ml for anti-B7-1 and anti-B7-2, respectively. For cross- 
linking assays, anti-CD8 was added at 4 #g/ml, anti-CD3 was added 
at 5 #g/ml, anti-CTLA-4 was added at 20 #g/ml, and anti-Vy3 
control antibody F536 was added to produce aconstant total anti- 
body concentration f 30 #g/ml. Polyclonal goat anti-hamster anti- 
body (Pierce Chemical Co., Rockford, IL) was added at a final con- 
centration of 20 #g/ml. All cultures were incubated at 37~ for 
72 h, then pulsed with 1 #Ci of [3H]thymidine for an additional 
16 h before harvesting. 
Antibody Incorporation onto Latex Microspheres. Sulfate polysty- 
rene latex microspheres of 5 +_ 0.1 #M mean diameter were ob- 
tained from Interracial Dynamics Corporation (Portland, OR). Ap- 
proximately 1 x 107 beads per ml were suspended in PBS and the 
indicated antibodies were incubated for 1.5 h at 370C. Anti-CD3 
was added at 1 tzg/ml to deliver the antigen-specific signal, and 
binding solutions were normalized with control antibody 536 to 
maintain aconstant total antibody concentration f 5 #g/rot during 
binding. Previous data have shown maximal binding is achieved 
when this concentration is added per 107 particles (36). Beads were 
washed extensively with PBS and resuspended in I ml RPMI-10% 
FCS and allowed to block for at least 30 min at room temperature. 
1@ cells were incubated in 96-well cultures with 10 s each of the 
indicated bead preparation. 
Results 
Activation Induces Expression of CTLA-4 on Both CD4 + and 
CD8 + T cells. Antibody 9H10 was used to assess CTLA-4 
expression on freshly isolated and activated T cells. As shown 
in Fig. 1 A, CTLA-4 was undetectable on freshly isolated 
T cells. CTLA-4 was readily detected on T cells 48 h after 
stimulation by addition of anti-CD3 to splenocytes, and it 
was returned to resting levels by 72 h. CD28 expression was 
not greatly altered by stimulation. CTLA-4 was expressed 
by both CD4 § and CD8 § T cells, with significantly higher 
levels on the latter. 
Blockade of CTLA-4 or B7-I/2 Enhances Anti-CD28 Costimu- 
lation. To determine the functional consequences of CTLA-4 
engagement, soluble anti-CTLA-4 or anti-CD28 antibodies 
were added singly or together to cultures of purified T cells 
exposed to immobilized anti-CD3. As shown in Fig. 2, while 
anti-CD28 greatly enhances the minimal proliferation i duced 
by CD3 stimulation, anti-CTLA-4 has no effect. This sug- 
gests that CTLA-4 does not function as an alternate costimula- 
tory receptor. Despite its lack of costimulatory activity on 
its own, anti-CTLA-4 markedly increases T cell prolifera- 
tion when given together with anti-CD28. 
At least two mechanisms could account for the potentiating 
effects of anti-CTLA-4: enhancement of activation signals 
or removal of inhibitory signals. Given the observation that 
anti-CTLA-4 lacked costimulatory activity on its own, we 
favored the latter possibil ity- that blockade of CTLA-4 by 
the antibody might prevent interaction of CTLA-4 on the 
T cell surface with B7-1 and/or B7-2 and thus prevent delivery 
of an inhibitory signal. This is further suggested by the ob- 
servation that anti-CTLA-4 Fab fragments have similar effects 
as anti-CTLA-4 mAbs in this assay system (data not shown). 
Since the cells used in our experiments were >99% Thyl  + 
and contained no detectable MHC class-II + or B220 + cells, 
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Figure 2. Influence of anti-CTLA-4 and anti-B7 antibodies on prolifer- 
ative responses of purified lymph node T cells. 105 BALB/c LN T cells 
were cultured for 72 h in 96-weU microwells coated with 0.1 #g/ml anti- 
CD3. Anti-CD28 was used at a 1:1,000 dilution of ascites and B7 anti- 
bodies were used at 2.5 and 10 #g/ml for anti-B7-1 and anti-B7-2, respec- 
tively. Anti-CTLA-4 antibody 9H10 was added at 10 ~g/ml. 
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Figure 1. Expression of CTLA-4 and CD28 on resting and activated 
splenic T cells. BALB/c splenic ell suspensions (2 x 10S/ml) were stimu- 
lated in vitro with 10/~g/ml soluble anti-CD3. (a) Cells were double stained 
with Thyl.2PE and either hamster Ig-control FITC, anti-CTLA-4 FITC, 
or anti-CD28 FITC. Data were electronically gated for Thyl.2-positive 
cells; CTLA-4 and CD28 expressions are shown on freshly explanted cells 
and after 48- and 72-h incubations with anti-CD3. (b) 48-h cultures were 
stained for anti-CD4 biotin or anti-CD8 biotin followed by avidin tri- 
color and FITCylated irrelevant or CTLA-4 antibodies. Subpopulation- 
gated ata show modestly higher CTLA-4 expression  CD8 populations. 
this possibility would require that the T cells themselves pro- 
vide a source of ligand. As shown in Fig. 3, flow cytometric 
analysis revealed that the freshly isolated T cells did indeed 
express ignificant levels of B7-2 and trace levels of B7-1. 
To determine the functional consequence of B7 expression 
by T cells in our assay system, we determined the effects of 
anti-B7 antibodies on CD28-mediated costimulation. As 
shown in Fig. 2, anti-B7 antibodies by themselves had no 
significant effect on anti-CD3-induced T cell proliferation. 
The addition of anti-B7 antibodies to cultures containing anti- 
CD28 resulted in a threefold increase in proliferation over 
that obtained with anti-CD28 alone. A similar increase in 
proliferation was obtained when chimeric CTLA-4 Ig instead 
of anti-B7 antibodies was added to block B7 interactions (data 
not shown). The magnitude of the increase was similar to 
that obtained when anti-CTLA-4 is added to CD28-treated 
cells in the absence of B7 blockade. The addition of anti- 
CTLA-4 to cultures in which anti-B7 antibodies are present 
results in no further increase in CD28 costimulation; indeed, 
a slight but reproducible decrease is observed. 
Together, these results suggest hat T cells express B7 at 
levels that are insufficient to provide costimulation via CD28 
engagement in the assay system used. However, perhaps be- 
cause of the fact that CTLA-4 has a much higher affinity 
than CD28 for B7 binding, these levels are sufficient o generate 
a signal that at least partially inhibits activation. Blockade 
of the CTLA-4/B7 interaction with either anti-CTLA-4 or 
antioB7 antibodies removes the inhibitory signal, resulting 
in an increase of the costimulatory effect of CD28 ligation. 
Cross-linking of CTLA-4 with the TCR and CD28 Inhibits 
T Cell Proliferation and IL-2 Production. The results shown 
7 ? -~ ,27. t
Figure 3. Expression ofB7-2 and B7-1 on purified, freshly isolated lymph 
node T cells. Cells that were >99% Thyl.2 + were isolated and stained 
with GL1 (anti-B7-2), 1610A (anti-B7-1), or irrelevant antibodies. 
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in Fig. 2 suggested that soluble, bivalent anti-CTLA-4 anti- 
body was effective in blocking B7-mediated signals, but was 
inefficient in providing signals. We next examined the effects 
of using anti-hamster Ig to cross-link CD3, CD28, and 
CTLA-4 singly or together. As shown in Fig. 4, no prolifer- 
ation was obtained when CD3, CD28, or CTLA-4 were cross- 
linked individually. As expected, cross-linking of CD3 to- 
gether with CD28 resulted in potent costimulation, while 
cross-linking of CD3 and CTLA-4 had no effect. Co-cross- 
linking of CTLA-4 together with CD3 and CD28 consis- 
tently resulted in a 5- to 10-fold reduction in proliferation. 
This inhibition was largely reversed by the addition of IL-2 
to the cultures, suggesting that the effect is not caused by 
toxicity. Finally, cross-linking of CTLA-4 with CD3 and 
CD28 also resulted in a profound ecrease in IL-2 produc- 
tion in the cultures (Fig. 4 B). These results demonstrate that 
CTLA-4 can deliver signals that inhibit T cell responses to 
TCR ligation, and that the effects observed in the experi- 
mAb X- l inked  
C~rl t 
aCD3,Ctrl 1 
aCD2S,Ctrl 1 
aCTLA-4,Ctrl 1 
aCD3,aCD28.Ctrl-[~ !! ~:.~:.~:.! ! :. i:i:.~:.i iii il![[~:.i:. i:.i ;.:.~i~:. i:.:.i i :.ii!i:.  :.i:. ~ I - - I 
ac~D3aca~A-4aCTL:~ ~ 
aCD3,aCD28 ,aCTLA-4JL2 '-~ i!i!ii!iiii::!!ii~i!:i!i!i!::~i~i!::~i~i!::!::!~ ] -I 
I I I I i 
0 50000 100000 150000 20~C00 250000 
cpm 
MAb )[- l inked 
aCD28~"CU'[ - ~  
aCTLA-4-',Ctrl - 
aCD3+Ctrl - 
aCD3+aCTLA-4-t(2trt - ~  
aCD3+aCD28+aCTLA4 - 
T 0 5 10 15 20 25 
IL2 (ng/ml) 
Figure 4. Cross-linked anti-CTLA-4 can diminish both proliferation 
and lymphokine production by purified LN T cells. 10s BALB/c LN T 
cells were cultured with the indicated hamster antibodies together with 
control hamster antibodies. Anti-hamster Ig antibody was added at 20 
/~g/ml to cross-link. Where indicated, anti-CD3 was added at 5 ~tg/ml, 
anti-CD28 was added at 4 ~g/ml, anti-CTLA-4 was added at 20 #g/ 
ml, and control was added to normalize antibody concentration at 30 p.g/ml. 
(a) Calls were cultured for 72 h, pulsed with 1 ~Ci [3H]thymidine, and 
harvested after an additional 16 h. (b) Supernatants were removed and ana- 
lyzed for II.-2 production at48 h using an ELISA detection system. 
ment presented in Fig. 2 most likely result from perturba- 
tion of B7/CTLA-4 interactions. 
CD28 and CTLA-4 Deliver Quantitatively Opposing Sig- 
nals. The preceding data indicate that CTLA-4 cross-linking 
in the presence of CD28 signaling can inhibit IL-2 secretion 
and proliferation. We next sought o determine whether sig- 
naling above the threshold for CTLA-4 inhibition is inde- 
pendent of the magnitude of CD28 costimulation, or whether 
the threshold increases as CD28 signaling increases. To ad- 
dress this issue, T cells were stimulated by incubation with 
polystyrene beads coated with a constant amount of anti- 
CD3 and varying amounts of anti-CD28 and anti-CTLA-4. 
As shown in Fig. 5, costimulation with increasing amounts 
of anti-CD28 in the absence of anti-CTLA-4 resulted in a 
gradual increase in proliferation, reaching at the highest dose 
a 1,500-fold increase over that obtained with anti-CD3 alone. 
The addition of increasing amounts of anti-CTLA-4 reduced 
that proliferation i  a stepwise manner at all doses of anti- 
CD28. These results suggest hat T cells integrate signals 
from CD28 with signals from CTLA-4, and the balance 
of these signals regulates the magnitude of the response to 
TCR ligation. 
Discussion 
The results presented here clearly demonstrate that CTLA-4 
does not serve as a functional alternative to CD28 in providing 
costimulatory signals to T cells. This finding is in agreement 
with earlier studies showing that CTLA-4 did not replace 
CD28 function in CD28 mutant mice (37). The finding that 
anti-CTLA-4 increases proliferation of T cells activated by 
anti-CD3 and anti-CD28 is in agreement with the results 
of Linsley et al. (24). However, the fact that a similar result 
is obtained when blocking antibodies to B7 are included sug- 
gests that this apparent cooperativity of CTLA-4 is in fact 
a result of removal of preexisting inhibitory B7-CTLA-4 in- 
Figure 5. Proliferation in response to a constant CD3 signal is affected 
by the relative concentrations f CD28 and CTLA-4 signals. 107 5 ~tM 
microspheres were coated with 1 ~tg/ml of anti-CD3, the indicated con- 
centrations of anti-CD28 and anti-CTLA-4, and control hamster Igcon- 
stituting a total antibody concentration of 5 pg/ml. 10 s coated spheres 
were incubated in 96-well cultures with 10 s purified LN T calls for 72 h, 
pulsed with 1 ~tCi [3H]thymidine, and harvested after an additional 16 h. 
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teractions by the soluble CTLA-4 antibodies rather than a 
synergism between the two antibody-generated signals. The 
ability of CTLA-4 to directly signal is supported by the fact 
that cross-linking of anti-CTLA-4, either with second anti- 
body or by presentation immobilized on beads, results in in- 
hibition of both IL-2 production and proliferation. This di- 
rect demonstration of signaling by CTLA-4 supports the 
report of Walunas et al. (26) that CTLA-4 is a negative regu- 
lator of T cell activation. 
Our demonstration of a dynamic ompetition between 
CD28 and CTLA-4 indicates that in addition to CD3 and 
CD28 signal integration, there exists an integration point 
for CTLA-4-derived signals. At present there is little knowl- 
edge of the biochemical events that follow CD28 or CTLA-4 
ligation. There have been reports that CD28 stimulation results 
in induction of protein tyrosine kinase activity (38), and re- 
cent evidence suggest he Tec family kinase ITK represents 
one associated protein kinase (39). In addition, it has been 
demonstrated that phosphoinositides accumulate in T cells 
stimulated by ligation of CD28 with B7-1, suggesting an 
involvement of phosphatidylinositol 3'-kinase (PI3K) 1 with 
CD28 (40). In this regard, it is of interest that the cytoplasmic 
domains of both CD28 and CTLA-4 contain the sequence 
YM/VXM, a motif found in several growth factor eceptors 
that associate with PI3K (41, 42). Several recent reports have 
documented a stimulation-induced association between CD28 
and PI3K, and it has been reported that mutation of the PI3K- 
binding motif destroys the costimulatory activity of CD28 
(43-47). These findings trongly suggest that binding of PI3K 
plays an important role in CD28 signaling. With respect to 
CTLA-4, however, there have been contradictory findings. 
Whereas achimeric protein containing the cytoplasmic do- 
main of CTLA-4 was unable to bind PI3K (46), another study 
1 Abbreviation used in this paper: PI3K, phosphatidylinositol 3'-kinase. 
reported the coprecipitation f PI3K activity with CTLA-4 
(48). In any event, these findings raise the possibility that 
CD28 and CTLA-4 might compete for PI3K and affect its 
role in subsequent signal transduction. 
It is also possible that CD28 and CTLA-4 signals might 
intersect at later stages in the pathway. It has been demon- 
strated that the CD28 and CD3 pathways intersect at the 
level of the MAP kinase JNK (49). CTLA-4 might in someway 
interfere with this coupling, thus preventing costimulation. 
Finally, it is possible that CTLA-4 signals might interfere 
with those of CD28 even further downstream by interfering 
with IL-2 transcriptions or mRNA stabilization (46, 50). 
Our results further suggest that regulation of the outcome 
of T cell stimulation isa complex process with regard to events 
at the cell surface. It is clear that in the absence of costimula- 
tory signals provided by the B7 family, T cells do not 
proliferate. It appears that even small amounts of B7, such 
as those present on T cells themselves, are ineffectual in sup- 
porting CD28-mediated costimulation ofanti-CD3 responses. 
This appears to be less a consequence of the absence of CD28 
signal being delivered, but rather a result of an inhibitory 
signal delivered through CTLA-4. This implies that either 
CTLA-4 is quickly expressed after activation and aborts the 
response, or that CTLA-4 is expressed at functionally 
significant levels on resting T cells. At higher levels of B7 
expression, as might be encountered on activated endritic 
cells and activated B cells, CTLA-4 expression on the T cells 
might become limiting, and the costimulation provided by 
CD28 becomes dominant. As expression of CTLA-4 rises 
after activation, the signals generated through CTLA-4 might 
become dominant and terminate the response. Decay of 
CTLA-4 expression with time would allow the T cell to re- 
turn to a state where the CD28 costimulatory signal would 
predominate. In any event, accumulating evidence suggests 
that in addition to antigen receptor and CD28-mediated 
signals, a third signal, provided by CTLA-4, is important 
in determining the outcome of T cell activation. 
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